Company Profile

Issar S Purposelies In Thedevelopment Of New Technologies At An Affordablepriceto Improvequality Of Lifefor Indian Populationwith Over 25 Years Of Experienceand Primefocus In Research And Developmentissar S Dedicated Team Of Experts Areproud To Havedeveloped India S First Ever Peptidemoleculemelgain For Thetreatment Of Vitiligo In 2004Which Is Now Introduced As Novoskinawith Improved Properties And Effectivenessissar Scommitment Has Also Led To Thedevelopment Of Their Second New Chemical Entity Called Xylentraa Which Is Thefirst Ever Peptidedrug In Theworld For Thetreatment Of Burn Wounds And Microbial Infections Recentlyissar Has Also Developed Molecules For Prevalent Conditions In Thewestern World Such As Inflammatory Bowel Diseasesibd Psoriasis And Sepsis Thefutureholds An Extensiveplacefor Peptides As Safeand Efficient Therapeutics With Excellent Diagnosticpreventiveand Curativepropertiesissar Is Theonly Pharmaceutical Company Working As A Purely Peptidemanufacturing Technology Based Company With An Fdacompliant Stateof Theart Manufacturing Facility Of 62000 Sqftlocated In Genomevalleyhyderabadindiain Addition To Its Experiencein R&Dissar Is Equipped With Themost Advanced And Automated Technology For Synthesis And Purification Of Peptidesproducing Highest Standards Of Purity Of Up To 99 5By Continued Process Optimization Issar Uses Solid Phasepeptidesynthesis As Thetechnology Of Choicewith A Long Standing Expertisein Custom Peptidesynthesis At All Scaleswith Our Emphasis On Qualitysafety And Innovationissar Has Demonstrated Theability To Moveproducts From Conceptualisation To Commercialisation Of Peptidemolecules At All Stagesissar Has Several Patents For Potential Lifechanging Peptidemolecules Lined Up In Their Development Pipelinetargeting Therapeutic Areas Such As Oncologydermatologygastroenterology And Diseases Of Bones And Joints